---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-017209"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T03:59:35.712911+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma amends agreement with Cytovance to raise ownership cap from 4.9% to 9.9%

## Summary
- Cytovance's beneficial ownership limit raised from 4.9% to 9.9% of GT Biopharma's outstanding common stock.
- Amendment effective April 25, 2024; all other terms of the Aug 24, 2022 Settlement and Investment Agreement unchanged.
- Excess shares above 9.9% cap to be issued in quarterly installments with 10-day prior notice from GTBP.
- Executed by GTBP Executive Chairman Michael Breen and Cytovance CFO David Knauss.

## SEC filing metadata
- accession: 0001493152-24-017209
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315224017209/0001493152-24-017209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315224017209/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-017209
- JSON: https://secwatch.observer/filing/0001493152-24-017209.json
- Plain text: https://secwatch.observer/filing/0001493152-24-017209.txt

## Key facts
- Material Agreements
  GT Biopharma, Inc. amended Amendment No. 1 to Settlement and Investment Agreement with Cytovance Biologics, Inc. (effective 2024-04-25).
  - Action: amendment
  - Agreement: settlement
  - Counterparty: Cytovance Biologics, Inc.
  - Effective: 2024-04-25
  source text: On April 25, 2024, the Registrant entered into Amendment No. 1 to Settlement and Investment Agreement (the “Amendment”) with Cytovance to increase the limit on Cytovance’s ownership of shares of the Registrant’s common stock from 4.9% to 9.9% of the outstanding shares of the Registrant’s common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000149315224017209/0001493152-24-017209-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.